Healthcare > XOLREMDI® (mavorixafor)

Tracking since May 19, 2026 · Latest signal Apr 29, 2026 · 3 matched data points

Overall sentiment

Positive 100% (3)Negative 0% (0)Neutral 0% (0)

Daily sentiment

Claims (1)

Claims contributing to this aggregate. Confirmed negative claims count as negative impact; confirmed positive claims count as positive impact.

The European Commission has authorized XOLREMDI® (mavorixafor) as the first treatment for WHIM syndrome in the European Union.

Parent: HealthcareEntity: XOLREMDI® (mavorixafor)Impact: positiveDate: Apr 29, 2026Target: European Commission's approval of XOLREMDI® (mavorixafor) for WHIM syndrome3 matched entries3 confirmed0 disputed0 neutral0 unclear